Why Is Coinbase Stock Going Down?
Every way you look at it, Coinbase has had a…
Sell
25
OZEM Quote, Financials, Valuation and Earnings
Last price:
$24.70
Seasonality move
:
--
Day range:
$24.68 - $24.94
52-week range:
$24.33 - $29.21
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
15.1K
Avg. volume:
28.9K
1-year change:
--
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
OZEM
Roundhill GLP-1 & Weight Loss ETF
|
-- | -- | -- | -- | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
GDOC
Goldman Sachs Future Health Care Equity ETF
|
-- | -- | -- | -- | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
OZEM
Roundhill GLP-1 & Weight Loss ETF
|
$24.80 | -- | -- | -- | $0.00 | 0% | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
$27.24 | -- | -- | -- | $0.13 | 1.65% | -- |
|
GDOC
Goldman Sachs Future Health Care Equity ETF
|
$32.54 | -- | -- | -- | $0.01 | 0.02% | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
$21.75 | -- | -- | -- | $0.06 | 1.13% | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
$23.12 | -- | -- | -- | $0.00 | 0% | -- |
|
XBI
SPDR S&P Biotech ETF
|
$91.35 | -- | -- | -- | $0.00 | 0.15% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
OZEM
Roundhill GLP-1 & Weight Loss ETF
|
-- | 0.000 | -- | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
-- | 1.073 | -- | -- |
|
GDOC
Goldman Sachs Future Health Care Equity ETF
|
-- | 1.154 | -- | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
-- | 1.252 | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | 0.000 | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | 2.133 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
OZEM
Roundhill GLP-1 & Weight Loss ETF
|
-- | -- | -- | -- | -- | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
GDOC
Goldman Sachs Future Health Care Equity ETF
|
-- | -- | -- | -- | -- | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- | -- |
Roundhill GLP-1 & Weight Loss ETF vs. Competitors
-
Which has Higher Returns OZEM or FTXH?
First Trust Nasdaq Pharmaceuticals ETF has a net margin of -- compared to Roundhill GLP-1 & Weight Loss ETF's net margin of --. Roundhill GLP-1 & Weight Loss ETF's return on equity of -- beat First Trust Nasdaq Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- FTXHFirst Trust Nasdaq Pharmaceuticals ETF-- -- -- -
What do Analysts Say About OZEM or FTXH?
Roundhill GLP-1 & Weight Loss ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust Nasdaq Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Roundhill GLP-1 & Weight Loss ETF has higher upside potential than First Trust Nasdaq Pharmaceuticals ETF, analysts believe Roundhill GLP-1 & Weight Loss ETF is more attractive than First Trust Nasdaq Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings OZEMRoundhill GLP-1 & Weight Loss ETF0 0 0 FTXHFirst Trust Nasdaq Pharmaceuticals ETF0 0 0 -
Is OZEM or FTXH More Risky?
Roundhill GLP-1 & Weight Loss ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison First Trust Nasdaq Pharmaceuticals ETF has a beta of 0.658, suggesting its less volatile than the S&P 500 by 34.157%.
-
Which is a Better Dividend Stock OZEM or FTXH?
Roundhill GLP-1 & Weight Loss ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. First Trust Nasdaq Pharmaceuticals ETF offers a yield of 1.65% to investors and pays a quarterly dividend of $0.13 per share. Roundhill GLP-1 & Weight Loss ETF pays -- of its earnings as a dividend. First Trust Nasdaq Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OZEM or FTXH?
Roundhill GLP-1 & Weight Loss ETF quarterly revenues are --, which are smaller than First Trust Nasdaq Pharmaceuticals ETF quarterly revenues of --. Roundhill GLP-1 & Weight Loss ETF's net income of -- is lower than First Trust Nasdaq Pharmaceuticals ETF's net income of --. Notably, Roundhill GLP-1 & Weight Loss ETF's price-to-earnings ratio is -- while First Trust Nasdaq Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roundhill GLP-1 & Weight Loss ETF is -- versus -- for First Trust Nasdaq Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- -- FTXHFirst Trust Nasdaq Pharmaceuticals ETF-- -- -- --
-
Which has Higher Returns OZEM or GDOC?
Goldman Sachs Future Health Care Equity ETF has a net margin of -- compared to Roundhill GLP-1 & Weight Loss ETF's net margin of --. Roundhill GLP-1 & Weight Loss ETF's return on equity of -- beat Goldman Sachs Future Health Care Equity ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- GDOCGoldman Sachs Future Health Care Equity ETF-- -- -- -
What do Analysts Say About OZEM or GDOC?
Roundhill GLP-1 & Weight Loss ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Goldman Sachs Future Health Care Equity ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Roundhill GLP-1 & Weight Loss ETF has higher upside potential than Goldman Sachs Future Health Care Equity ETF, analysts believe Roundhill GLP-1 & Weight Loss ETF is more attractive than Goldman Sachs Future Health Care Equity ETF.
Company Buy Ratings Hold Ratings Sell Ratings OZEMRoundhill GLP-1 & Weight Loss ETF0 0 0 GDOCGoldman Sachs Future Health Care Equity ETF0 0 0 -
Is OZEM or GDOC More Risky?
Roundhill GLP-1 & Weight Loss ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Goldman Sachs Future Health Care Equity ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock OZEM or GDOC?
Roundhill GLP-1 & Weight Loss ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Goldman Sachs Future Health Care Equity ETF offers a yield of 0.02% to investors and pays a quarterly dividend of $0.01 per share. Roundhill GLP-1 & Weight Loss ETF pays -- of its earnings as a dividend. Goldman Sachs Future Health Care Equity ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OZEM or GDOC?
Roundhill GLP-1 & Weight Loss ETF quarterly revenues are --, which are smaller than Goldman Sachs Future Health Care Equity ETF quarterly revenues of --. Roundhill GLP-1 & Weight Loss ETF's net income of -- is lower than Goldman Sachs Future Health Care Equity ETF's net income of --. Notably, Roundhill GLP-1 & Weight Loss ETF's price-to-earnings ratio is -- while Goldman Sachs Future Health Care Equity ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roundhill GLP-1 & Weight Loss ETF is -- versus -- for Goldman Sachs Future Health Care Equity ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- -- GDOCGoldman Sachs Future Health Care Equity ETF-- -- -- --
-
Which has Higher Returns OZEM or IBBQ?
Invesco Nasdaq Biotechnology ETF has a net margin of -- compared to Roundhill GLP-1 & Weight Loss ETF's net margin of --. Roundhill GLP-1 & Weight Loss ETF's return on equity of -- beat Invesco Nasdaq Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- IBBQInvesco Nasdaq Biotechnology ETF-- -- -- -
What do Analysts Say About OZEM or IBBQ?
Roundhill GLP-1 & Weight Loss ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Nasdaq Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Roundhill GLP-1 & Weight Loss ETF has higher upside potential than Invesco Nasdaq Biotechnology ETF, analysts believe Roundhill GLP-1 & Weight Loss ETF is more attractive than Invesco Nasdaq Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings OZEMRoundhill GLP-1 & Weight Loss ETF0 0 0 IBBQInvesco Nasdaq Biotechnology ETF0 0 0 -
Is OZEM or IBBQ More Risky?
Roundhill GLP-1 & Weight Loss ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Invesco Nasdaq Biotechnology ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock OZEM or IBBQ?
Roundhill GLP-1 & Weight Loss ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Invesco Nasdaq Biotechnology ETF offers a yield of 1.13% to investors and pays a quarterly dividend of $0.06 per share. Roundhill GLP-1 & Weight Loss ETF pays -- of its earnings as a dividend. Invesco Nasdaq Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OZEM or IBBQ?
Roundhill GLP-1 & Weight Loss ETF quarterly revenues are --, which are smaller than Invesco Nasdaq Biotechnology ETF quarterly revenues of --. Roundhill GLP-1 & Weight Loss ETF's net income of -- is lower than Invesco Nasdaq Biotechnology ETF's net income of --. Notably, Roundhill GLP-1 & Weight Loss ETF's price-to-earnings ratio is -- while Invesco Nasdaq Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roundhill GLP-1 & Weight Loss ETF is -- versus -- for Invesco Nasdaq Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- -- IBBQInvesco Nasdaq Biotechnology ETF-- -- -- --
-
Which has Higher Returns OZEM or THNR?
Amplify Weight Loss Drug & Treatment ETF has a net margin of -- compared to Roundhill GLP-1 & Weight Loss ETF's net margin of --. Roundhill GLP-1 & Weight Loss ETF's return on equity of -- beat Amplify Weight Loss Drug & Treatment ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -
What do Analysts Say About OZEM or THNR?
Roundhill GLP-1 & Weight Loss ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Amplify Weight Loss Drug & Treatment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Roundhill GLP-1 & Weight Loss ETF has higher upside potential than Amplify Weight Loss Drug & Treatment ETF, analysts believe Roundhill GLP-1 & Weight Loss ETF is more attractive than Amplify Weight Loss Drug & Treatment ETF.
Company Buy Ratings Hold Ratings Sell Ratings OZEMRoundhill GLP-1 & Weight Loss ETF0 0 0 THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 -
Is OZEM or THNR More Risky?
Roundhill GLP-1 & Weight Loss ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock OZEM or THNR?
Roundhill GLP-1 & Weight Loss ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amplify Weight Loss Drug & Treatment ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roundhill GLP-1 & Weight Loss ETF pays -- of its earnings as a dividend. Amplify Weight Loss Drug & Treatment ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OZEM or THNR?
Roundhill GLP-1 & Weight Loss ETF quarterly revenues are --, which are smaller than Amplify Weight Loss Drug & Treatment ETF quarterly revenues of --. Roundhill GLP-1 & Weight Loss ETF's net income of -- is lower than Amplify Weight Loss Drug & Treatment ETF's net income of --. Notably, Roundhill GLP-1 & Weight Loss ETF's price-to-earnings ratio is -- while Amplify Weight Loss Drug & Treatment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roundhill GLP-1 & Weight Loss ETF is -- versus -- for Amplify Weight Loss Drug & Treatment ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- -- THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- --
-
Which has Higher Returns OZEM or XBI?
SPDR S&P Biotech ETF has a net margin of -- compared to Roundhill GLP-1 & Weight Loss ETF's net margin of --. Roundhill GLP-1 & Weight Loss ETF's return on equity of -- beat SPDR S&P Biotech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- XBISPDR S&P Biotech ETF-- -- -- -
What do Analysts Say About OZEM or XBI?
Roundhill GLP-1 & Weight Loss ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Biotech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Roundhill GLP-1 & Weight Loss ETF has higher upside potential than SPDR S&P Biotech ETF, analysts believe Roundhill GLP-1 & Weight Loss ETF is more attractive than SPDR S&P Biotech ETF.
Company Buy Ratings Hold Ratings Sell Ratings OZEMRoundhill GLP-1 & Weight Loss ETF0 0 0 XBISPDR S&P Biotech ETF0 0 0 -
Is OZEM or XBI More Risky?
Roundhill GLP-1 & Weight Loss ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison SPDR S&P Biotech ETF has a beta of 0.956, suggesting its less volatile than the S&P 500 by 4.394%.
-
Which is a Better Dividend Stock OZEM or XBI?
Roundhill GLP-1 & Weight Loss ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SPDR S&P Biotech ETF offers a yield of 0.15% to investors and pays a quarterly dividend of $0.00 per share. Roundhill GLP-1 & Weight Loss ETF pays -- of its earnings as a dividend. SPDR S&P Biotech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OZEM or XBI?
Roundhill GLP-1 & Weight Loss ETF quarterly revenues are --, which are smaller than SPDR S&P Biotech ETF quarterly revenues of --. Roundhill GLP-1 & Weight Loss ETF's net income of -- is lower than SPDR S&P Biotech ETF's net income of --. Notably, Roundhill GLP-1 & Weight Loss ETF's price-to-earnings ratio is -- while SPDR S&P Biotech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roundhill GLP-1 & Weight Loss ETF is -- versus -- for SPDR S&P Biotech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- -- XBISPDR S&P Biotech ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Uber Stock a Buy on the Dip?
Shares of Uber Technologies (NYSE:UBER) have been fading fast in…
Is AMD Stock an All-Time Buy?
Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 28
Lemonade [LMND] is down 10.69% over the past day.
Sell
50
TSLL alert for Dec 28
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 9.92% over the past day.
Buy
63
SMLR alert for Dec 28
Semler Scientific [SMLR] is down 9.65% over the past day.
